Serogroup B Protein Meningococcal Vaccines and the Formation of Immune Protection against Gonorrhea

Relevance. Gonorrhea is a widespread infection. More than 80 million cases of this disease occur annually. The problem is compounded by the growing resistance of gonococcus to antibiotics worldwide. The only way out in this situation may be the immunization of certain groups of the population agains...

Full description

Saved in:
Bibliographic Details
Main Authors: N. N. Kostyukova, V. A. Bekhalo
Format: Article
Language:Russian
Published: Numikom LLC 2024-07-01
Series:Эпидемиология и вакцинопрофилактика
Subjects:
Online Access:https://www.epidemvac.ru/jour/article/view/2021
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849690076407136256
author N. N. Kostyukova
V. A. Bekhalo
author_facet N. N. Kostyukova
V. A. Bekhalo
author_sort N. N. Kostyukova
collection DOAJ
description Relevance. Gonorrhea is a widespread infection. More than 80 million cases of this disease occur annually. The problem is compounded by the growing resistance of gonococcus to antibiotics worldwide. The only way out in this situation may be the immunization of certain groups of the population against this infection. Despite the numerous efforts of specialists, there is currently no registered vaccine against gonorrhea, which is due to the characteristics of the pathogen. However, over the past 30 years, reliable observations have accumulated that vaccines containing N. meningititidis serogroup B outer membrane proteins (OMP), developed for prophylaxis meningococcal infection, can also prevent a significant proportion of gonorrhea cases. Aims. To give a brief overview of publications on the reduction of the incidence of gonorrhea in individuals who received vaccines containing N. meningitidis serogroup B outer membrane vesicles, followed by an analysis of information about the nature of these proteins and methods of their study, as a promising platform for creating a vaccine against gonococcus. Conclusions. There is a theoretical and real possibility of creating a preventive drug against gonorrhea. Our analysis of literature sources showed that during the period 2006–2016 from 31% to 59% of those vaccinated with the protein meningococcal vaccine В were protected from gonorrhea. It is necessary to continue studying meningococcal OMV in terms of their preventive properties against gonorrhea, improve the set of models to identify their protective effect, and find adjuvants that enhance the immunogenicity of potential vaccine candidates.
format Article
id doaj-art-027e67231f084f69964367d1b80db767
institution DOAJ
issn 2073-3046
2619-0494
language Russian
publishDate 2024-07-01
publisher Numikom LLC
record_format Article
series Эпидемиология и вакцинопрофилактика
spelling doaj-art-027e67231f084f69964367d1b80db7672025-08-20T03:21:26ZrusNumikom LLCЭпидемиология и вакцинопрофилактика2073-30462619-04942024-07-0123312913610.31631/2073-3046-2024-23-3-129-1361042Serogroup B Protein Meningococcal Vaccines and the Formation of Immune Protection against GonorrheaN. N. Kostyukova0V. A. Bekhalo1N.F. Gamaleya National Rerearch Center of Epidemiology and MicrobiologyN.F. Gamaleya National Rerearch Center of Epidemiology and MicrobiologyRelevance. Gonorrhea is a widespread infection. More than 80 million cases of this disease occur annually. The problem is compounded by the growing resistance of gonococcus to antibiotics worldwide. The only way out in this situation may be the immunization of certain groups of the population against this infection. Despite the numerous efforts of specialists, there is currently no registered vaccine against gonorrhea, which is due to the characteristics of the pathogen. However, over the past 30 years, reliable observations have accumulated that vaccines containing N. meningititidis serogroup B outer membrane proteins (OMP), developed for prophylaxis meningococcal infection, can also prevent a significant proportion of gonorrhea cases. Aims. To give a brief overview of publications on the reduction of the incidence of gonorrhea in individuals who received vaccines containing N. meningitidis serogroup B outer membrane vesicles, followed by an analysis of information about the nature of these proteins and methods of their study, as a promising platform for creating a vaccine against gonococcus. Conclusions. There is a theoretical and real possibility of creating a preventive drug against gonorrhea. Our analysis of literature sources showed that during the period 2006–2016 from 31% to 59% of those vaccinated with the protein meningococcal vaccine В were protected from gonorrhea. It is necessary to continue studying meningococcal OMV in terms of their preventive properties against gonorrhea, improve the set of models to identify their protective effect, and find adjuvants that enhance the immunogenicity of potential vaccine candidates.https://www.epidemvac.ru/jour/article/view/2021meningococcusgonorrheameningococcal vaccinesneisseria outer membrane proteinsmeningococcal gonorrhea vaccineimmune responsevaccine effectiveness
spellingShingle N. N. Kostyukova
V. A. Bekhalo
Serogroup B Protein Meningococcal Vaccines and the Formation of Immune Protection against Gonorrhea
Эпидемиология и вакцинопрофилактика
meningococcus
gonorrhea
meningococcal vaccines
neisseria outer membrane proteins
meningococcal gonorrhea vaccine
immune response
vaccine effectiveness
title Serogroup B Protein Meningococcal Vaccines and the Formation of Immune Protection against Gonorrhea
title_full Serogroup B Protein Meningococcal Vaccines and the Formation of Immune Protection against Gonorrhea
title_fullStr Serogroup B Protein Meningococcal Vaccines and the Formation of Immune Protection against Gonorrhea
title_full_unstemmed Serogroup B Protein Meningococcal Vaccines and the Formation of Immune Protection against Gonorrhea
title_short Serogroup B Protein Meningococcal Vaccines and the Formation of Immune Protection against Gonorrhea
title_sort serogroup b protein meningococcal vaccines and the formation of immune protection against gonorrhea
topic meningococcus
gonorrhea
meningococcal vaccines
neisseria outer membrane proteins
meningococcal gonorrhea vaccine
immune response
vaccine effectiveness
url https://www.epidemvac.ru/jour/article/view/2021
work_keys_str_mv AT nnkostyukova serogroupbproteinmeningococcalvaccinesandtheformationofimmuneprotectionagainstgonorrhea
AT vabekhalo serogroupbproteinmeningococcalvaccinesandtheformationofimmuneprotectionagainstgonorrhea